Chardan raised the firm’s price target on Palvella Therapeutics (PVLA) to $60 from $50 and keeps a Buy rating on the shares. The firm updates its model after the company’s Q2 results and affirmed timelines on four upcoming catalysts including Q4 data from the Phase 2 TOIVA trial in cutaneous venous malformations, Q1 of 2026 data from the Phase 3 SELVA trial in microcystic lymphatic malformations, disclosure of a 3rd indication for QTORIN rapamycin and a 2nd QTORIN platform candidate before 2025-end, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target
- Positive Buy Rating for Palvella Therapeutics Driven by Promising Phase 3 Trial Developments and Market Potential
- Palvella Therapeutics price target raised to $60 from $45 at Stifel
- Palvella Completes Enrollment in Phase 3 SELVA Trial
- Palvella Therapeutics reports Q2 EPS (86c), consensus (77c)